CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 311 enrolled
Drug / intervention
Pleconaril +1 moredrug
Likely dose
Pleconaril 1.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00394914
NCT00394914Phase 2Completed
CompareCT.gov

A Placebo-Controlled Study of the Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure

Merck Sharp & Dohme LLC·interventional·Posted Nov 2, 2006·Updated Jul 16, 2015

In Brief

A Phase 2 clinical trial evaluating Pleconaril and Placebo to Pleconaril for Asthma and 3 related conditions. Completed, enrolled 311 participants.

Detailed Summary

This is a randomized, multi-center, double-blind, placebo-controlled study evaluating the efficacy of pleconaril nasal spray in preventing asthma exacerbation and common cold symptoms in asthmatic participants exposed to picornavirus respiratory infections. Participants will be assigned treatment with pleconaril or placebo nasal spray for 7 days (14 doses). Participants will be followed for an additional 14 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Common Cold, Picornavirus Infection, Rhinovirus
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2, 2006
Enrollment StartAug 1, 2006
Primary CompletionApr 1, 2007
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 19.7 years ago

Interventions

Pleconarildrug

Pleconaril nasal suspension is supplied in a bottle containing 120 actuations. Each actuation contains 1.5 mg of pleconaril.

Placebo to Pleconarildrug

Placebo nasal suspension